Rapport Therapeutics (RAPP) Assets (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Assets of $497.6 million for Q1 2026, up 64.74% year-over-year from $302.1 million in Q1 2025, and down 2.89% quarter-over-quarter from $512.4 million in Q4 2025.
Rapport Therapeutics (RAPP) Assets (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Assets for 4 consecutive years, with $497.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 64.74% year-over-year to $497.6 million; the TTM figure through Mar 2026 stood at $497.6 million (up 64.74% YoY), while the FY2025 annual figure was $512.4 million, up 62.71% from the prior year.
- Assets fell to $497.6 million in Q1 2026 per RAPP's latest filing, from $512.4 million in the prior quarter.
- Across five years, Assets topped out at $535.3 million in Q3 2025 and bottomed at $155.4 million in Q4 2023.
- Historically, Assets has averaged $364.5 million across 4 years, with a median of $331.1 million in 2024.
- Annual changes were most pronounced in 2024 — Assets soared 102.63% — and 2025, when it declined 17.51%.
- Rapport Therapeutics' Assets stood at $155.4 million in 2023, then soared by 102.63% to $314.9 million in 2024, then surged by 62.71% to $512.4 million in 2025, then retreated by 2.89% to $497.6 million in 2026.
- Business Quant data shows RAPP's Assets at $497.6 million in Q1 2026, $512.4 million in Q4 2025, and $535.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 458.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 458.98 Mn |
| Mar 31, 2026 | 497.60 Mn |
| Dec 31, 2025 | 512.43 Mn |
| Sep 30, 2025 | 535.32 Mn |
| Jun 30, 2025 | 285.50 Mn |
| Mar 31, 2025 | 302.05 Mn |
| Dec 31, 2024 | 314.93 Mn |
| Sep 30, 2024 | 331.14 Mn |
| Jun 30, 2024 | 346.10 Mn |
| Dec 31, 2023 | 155.42 Mn |